The prognostic significance of leukocytosis in cervical cancer

Garcia-Arias, Alicia; Cetina, Lucely; Candelaria, Myrna; Robles, Enrique Rosales; Dueñas‐González, Alfonso

doi:10.1111/j.1525-1438.2007.00816.x

Cited by 30 publications

(21 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In cancer patients, leukocytosis may also be a surrogate for advanced disease burden not captured by stage classification. 44 There did not appear to be a correlation of VTE with use of prophylactic myeloid growth factors in our study. Further investigations into the role of leukocytes in cancerassociated thrombosis would be of interest.…”

Section: Discussionmentioning

confidence: 39%

Development and validation of a predictive model for chemotherapy-associated thrombosis

Khorana

Kuderer

Culakova

et al. 2008

Blood

1,835

1,667

View full text Add to dashboard Cite

Risk of venous thromboembolism (VTE)is elevated in cancer, but individual risk factors cannot identify a sufficiently highrisk group of outpatients for thromboprophylaxis. We developed a simple model for predicting chemotherapy-associated VTE using baseline clinical and laboratory variables. The association of VTE with multiple variables was characterized in a derivation cohort of 2701 cancer outpatients from a prospective observational study. A risk model was derived and validated in an independent cohort of 1365 patients from the same study. Five predictive variables were identified in a multivariate model: site of cancer (2 points for very high-risk site, 1 point for highrisk site), platelet count of 350 ؋ 10 9 /L or more, hemoglobin less than 100 g/L (10 g/dL) and/or use of erythropoiesisstimulating agents, leukocyte count more than 11 ؋ 10 9 /L, and body mass index of 35 kg/m 2 or more (1 point each). Rates of VTE in the derivation and validation cohorts, respectively, were 0.8% and 0.3% in low-risk (score ‫؍‬ 0), 1.8% and 2% in intermediate-risk (score ‫؍‬ 1-2), and 7.1% and 6.7% in high-risk (score > 3) category over a median of 2.5 months (Cstatistic ‫؍‬ 0.7 for both cohorts). This model can identify patients with a nearly 7% short-term risk of symptomatic VTE and may be used to select cancer outpatients for studies of thromboprophylaxis. IntroductionCancer and antineoplastic therapy are frequently complicated by the development of venous thromboembolism (VTE). Several risk factors for cancer-associated VTE have been described in recent studies and include primary site of cancer, presence of metastatic disease, and use of antineoplastic therapy including chemotherapy, hormonal therapy, surgery, and erythropoiesis-stimulating agents. [1][2][3][4] Cancer patients on active therapy are at greatest risk for development of VTE. In a population-based study, cancer was associated with a 4.1-fold greater risk of thrombosis, whereas the use of chemotherapy increased the risk 6.5-fold. 5,6 In women with stage II breast cancer, the risk of VTE decreases dramatically after chemotherapy is completed. 7,8 The occurrence of VTE has important implications for the cancer patient including requirement for chronic anticoagulation, possible delays in delivering chemotherapy, a high risk of recurrent VTE, risk of bleeding complications on anticoagulation, decreased quality of life, and consumption of health care resources. 9,10 Furthermore, cancer patients with VTE have a 2-fold or greater increase in mortality compared with cancer patients without VTE, even after adjusting for stage. 11,12 Indeed, thromboembolism is a leading cause of death in cancer patients. 13 Primary VTE prophylaxis can reduce deep vein thrombosis (DVT), pulmonary embolism (PE), and fatal PE in several highrisk populations such as hospitalized patients or in the postoperative setting. [14][15][16][17][18] In the cancer population, identification of patients most at risk for VTE followed by institution of effective prophylaxis could improve morbidity, m...

show abstract

Section: Discussionmentioning

confidence: 39%

Development and validation of a predictive model for chemotherapy-associated thrombosis

Khorana

Kuderer

Culakova

et al. 2008

Blood

1,835

1,667

View full text Add to dashboard Cite

show abstract

“…Leukocytosis was also previously identified as a risk factor for VTE in a cross-section of tumor types. [5] Garcia-Arias et al [15] reported that the leukocytosis level remained a significant predictor of survival in multivariate analyses and that leukocytosis was common in cervical cancer patients and had a negative prognostic significance. In our study, we found that the leukocyte count was significantly high in lymphomas according to breast, colorectal, lung, and gynecological cancers.…”

Section: Discussionmentioning

confidence: 98%

Pulmonary embolism and hematologic outcome in cancer patients initiating chemotherapy

et al. 2014

View full text Add to dashboard Cite

Purpose: The aim of this study was to determine the relationship between chemotherapy use and the frequency of pulmonary embolism (PE) and associated mortality, clinical, and biochemical parameters. An additional aim was to analyze computed tomography pulmonary angiography findings. Materials and Methods: The study population comprised 65 of 368 consecutive patients diagnosed with PE who underwent chemotherapy in the Medical Oncology Department. The study population had cancer of various origins, including breast, colorectal, lung, gynecological, gastric and pancreatic, lymphatic, and other sites. The patients' clinical records were reviewed for leukocyte and platelet count, mean platelet volume (MPV), neutrophil to lymphocyte ratio, and level of mortality. As the parameters were normally distributed, the correlation coefficients and their significance were calculated using Pearson's test. One-way analysis of variance was used to compare the leukocyte counts among the cancer groups. A t-test was used to compare the means of the platelet and leukocyte counts between the patients. A Chi-square test was used to compare binary outcomes for categorical variables. Patients who died in the 1 st year and others (survivors and patients who died after the 1 st year) were compared using multinomial logistic regression analysis. Results: When the patients who died in the 1 st year and the survivors were compared, there was a statistically significant difference in the platelet count between the two groups. The platelet count, MPV, and leukocyte count of the patients with PE were significantly high. The leukocyte count was also significantly high in patients with breast, colorectal, lung, and gynecological cancers. Conclusion: Our results indicate that in cancer patients with PE who undergo chemotherapy, the platelet count, MPV, and leukocyte count are significantly high.

show abstract

“…It could be linked to better diagnostic classification used, obesity, and more younger age at diagnosis. 13 Reagen and Wentz stated that adenocarcinoma was less sensitive to radiation that lead to poor survival of such type. Meanwhile Fletcher, et al also believed that poor survival of such type was linked to miometrial invasion, thus it could spare the radiation in most of treatment.…”

Section: Discussionmentioning

confidence: 99%

Radiotherapy Response of Cervical Cancer Patients at a Tertiary Referral Hospital in Indonesia

Winarto

Supriana

2017

Indones J Obstet Gynecol

View full text Add to dashboard Cite

Objective: To investigate the response of radiotherapy and related clinicopathologic characterictics on cervical cancer patients. Methods: This was a retrospective study. Subjects were patients diagnosed with cervical cancer stage IIA-IIIB who had undergone radiation therapy based on standard protocol in our hospital, during the period of January 2014 to December 2015. The clinical factors ofthose patients, such as age, Body Mass Index, blood pressure, hemoglobin level, blood leucocyte count, serum albumin, largest tumor diameter, the International Federation of Gynecology and Obstetrics (FIGO) staging, as well as pathologic characteristic, i.e histopathology and grading were recorded. During radiation protocol until 3months post radiation, we also noted any side effects of gastrointestinal tract, genitourinary tract, and hematologic. Evaluation of radiotherapy response was based on Response Evaluation Criteria in Solid Tumors (RECIST). Results: A total of 123 subjects were enrolled in this study. 84 cases or 68.29% was complete response, 30 cases or 24.39% was partial response, 6 cases or 4.88% was stabile response, and 3 cases or 2.44% was progressive. Based on gastrointestinal side effect, there was no side effect or grade 0 on 99 cases (80.49%), grade 1 on 20 cases (16.26%), grade 2 on 4 cases (3.25%), grade 3 on 0 case (0%). Based on side effect of genitourinary, there was no side effect or grade 0 on 105 cases (85.37%), grade 1 on 17 cases (13.82%), grade 2 on 1 case (0.81%), grade 3 on 0 case (0%). Based on hematologic side effects, there was no side effecton 108 cases (87.80%), grade 1 on 15 cases (12.20%), grade 2 on 0 case (0%), grade 3 on 0 case (0%). Largest tumor diameter was statistically significant, with p=0.036 (RR 2.64 (1.07-6.56)). Conclusion: The majority of definitive-curative radiotherapy response on cervical cancer stage IIA-IIIB was complete (68.29%). Acute side effects involving the gastrointestinal, genitourinary, and hematologic system were commonly can be tolerable during and 3 months post radiation therapy. Clinicopathologic characteristics significantly associated with the complete response of radiotherapy was the largest tumor diameter. Keywords: largest tumor diameter, radiation response, radiationside effect

show abstract

The prognostic significance of leukocytosis in cervical cancer

Cited by 30 publications

References 36 publications

Development and validation of a predictive model for chemotherapy-associated thrombosis

Development and validation of a predictive model for chemotherapy-associated thrombosis

Pulmonary embolism and hematologic outcome in cancer patients initiating chemotherapy

Radiotherapy Response of Cervical Cancer Patients at a Tertiary Referral Hospital in Indonesia

Contact Info

Product

Resources

About